FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 744 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... April 23, 2019 ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure... June 23, 2025 NHS staff shortages: What’s needed to build a sustainable cancer workforce? October 12, 2020 Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... July 6, 2022 Load more HOT NEWS How Decades of NCI Support Led to Groundbreaking Discoveries: The Story... ¿Qué son los biosimilares para el tratamiento del cáncer? Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active... What Is Scanxiety? How People With Cancer and Survivors Can Cope
